Methylphenidate for Depressed Cancer Patients Receiving Palliative Care
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether methylphenidate is an effective treatment
for depression and to document the safety and tolerability of methylphenidate in combination
with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill,
hospice and palliative care cancer patients. The investigators hypothesize that depressed
hospice and palliative care patients will be more likely to have a 50% reduction in scores on
a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared
to those patients who are taking a placebo plus an SSRI.
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development
Collaborator:
Oregon Health and Science University
Treatments:
Central Nervous System Stimulants Citalopram Dexetimide Methylphenidate Serotonin Serotonin Uptake Inhibitors